Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer

NCT03077841 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03077841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03077841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2/3
Overall status
Suspended
Start date
March 6, 2017
Completion date
November 8, 2027
Enrollment
928 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

ductal breast carcinoma in situ, early-stage breast carcinoma, invasive breast carcinoma, stage 0 breast cancer ajcc v6 and v7, stage i breast cancer ajcc v7, stage ia breast cancer ajcc v7, stage ib breast cancer ajcc v7, stage ii breast cancer ajcc v6 and v7, stage iia breast cancer ajcc v6 and v7, stage iib breast cancer ajcc v6 and v7